Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University of Michigan
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01432106CT.gov The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome | — | Withdrawn | — | — | — |
NCT01138423CT.gov Treatment of Adiposity Related hypErTension (TARGET) | — | Completed | — | — | — |
NCT01048047CT.gov Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients | — | Unknown | — | — | — |
NCT00797316CT.gov Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension | — | Completed | — | — | — |
NCT00772577CT.gov Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension | — | Completed | — | — | — |
NCT00498433CT.gov Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension | — | Terminated | — | — | — |
NCT00219141CT.gov Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension | — | Completed | — | — | — |
NCT00219115CT.gov A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypertensive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aliskiren (this asset) | University of Michigan | Approved | BB · 68 |
| Valsartan | University of Alabama at Birmingham | P4 | BBB |
| Hydrochlorothiazide | University of Kansas Medical Center | P4 | BBB |
| Losartan | Rong Zhang | P4 | BBB |
| Amlodipine | Jing Liu | P4 | BBB |
| Corpril | University of Michigan | P4 | BBB |
| Olmesartan Medoxomil | Virginia Polytechnic Institute and State University | P4 | BBB |
| Trandolapril | University of Florida | P4 | BBB |
| Cilnidipine | Boryung Pharmaceutical Co., Ltd | P4 | BBB |
+42 more in the Hypertensive Disorder cohort
Other indications for Aliskiren
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Abdominal Obesity-Metabolic Syndrome | — | P4 | B · 59 |
| Proteinuria | — | P4 | CCC · 54 |
| Diabetic Kidney Disease | — | P4 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aliskiren in Hypertensive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aliskiren-hypertensive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →